Study Summaries

OV-10: Cisplatin + Paclitaxel vs Cisplatin + Cyclophosphamide in Advanced Ovarian Cancer

JAVELIN Ovarian 200: Avelumab Alone or With Pegylated Liposomal Doxorubicin in Platinum-Resistant or Platinum-Refractory Ovarian Cancer

JAVELIN Ovarian 100: Avelumab With or After Frontline Chemotherapy in Previously Untreated Advanced Epithelial Ovarian Cancer

GOG 114: IP Cisplatin Plus IV Paclitaxel vs Standard IV Cisplatin/Paclitaxel in Stage III Ovarian Cancer

AGO-OVAR 2.5: Gemcitabine Plus Carboplatin versus Carboplatin in Platinum-Sensitive Recurrent Ovarian Cancer

GOG 184: Cisplatin/Doxorubicin +/- Paclitaxel After Surgery + RT in Advanced Endometrial Carcinoma

EORTC-55991 / MaNGO ILIADE-III: Adding Sequential Chemotherapy to Adjuvant Radiotherapy in High-Risk Endometrial Cancer

JGOG1082: Adjuvant Chemotherapy vs Concurrent Chemoradiotherapy After Radical Hysterectomy for High-Risk Cervical Cancer

Sacituzumab Govitecan in Recurrent Endometrial Cancer (NCT04251416)

Fulvestrant + Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer (NCT03643510)